Intervacc is trading at €0.05, down 6.83%, amid broader risk-off pressure; supplied market context shows a sharp sell-off across major U.S. indices and biotech.
- No new Intervacc-specific announcement was found for November 5; the latest major company news was November 3’s positive Strangvac update, reporting three confirmed infections after 100,000 doses sold.
- That earlier news accompanied the prior session’s rise but does not explain the current decline.
- No trading-volume data was available.